Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 31/10/22 → 1/01/24 |
Keywords
- Clinical trial
- depression
- Cognitive Impairment
- Alzheimer disease
Clinical Trial Phase
- Phase II
XanaCIDD: A Double-Blind, Randomized, Placebo Controlled, ParallelGroup Trial to Assess the Safety, Tolerability, and Efficacy of Xanamem® in Adults with Cognitive Impairment due to Depressive Disorder
- Chen, Leo (Primary Chief Investigator (PCI))
- Gavrilidis, Emorfia (Project Manager)
Project: Research